Valneva’s IXCHIQ Vaccine Demonstrates Long-Lasting Antibody Persistence as Industry Celebrates Innovation in Health...
Valneva SE, a specialist in vaccine development, announced promising data regarding the antibody persistence of its chikungunya vaccine, IXCHIQ. The company’s findings, released on December 3, 2024, reveal that the vacc...
Dec 3, 2024
• Semiconductors Industry
Product Service News
Baird These Technology